ArticleJournal of cell science2012
Foxk1 promotes cell proliferation and represses myogenic differentiation by regulating Foxo4 and Mef2.
Article in Journal of cell science, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 62 citations in OpenAlex.
- FOXK1: a multifaceted regulator in metabolic reprogramming and disease progression.Biology direct · 2026Review
- FOXK1 promotes hormonally responsive breast carcinogenesis by suppressing apoptosis.Animal models and experimental medicine · 2025Article
- Foxk1 and Foxk2 promote cardiomyocyte proliferation and heart regeneration.Nature communications · 2025Article
- Combating chronic kidney disease-associated cachexia: A literature review of recent therapeutic approaches.BMC nephrology · 2025Review
- The LncRNA lnc-POTEM-4:14 promotes HCC progression by interacting with FOXK1.Scientific reports · 2025Article
- Foxk1 promotes bone formation through inducing aerobic glycolysis.Cell death and differentiation · 2024Article
- circ-ATAD1 as Competing Endogenous RNA for miR-191-5p Forces Non-small Cell Lung Cancer Progression.Applied biochemistry and biotechnology · 2024Article
- Exploiting the Warburg Effect: Co-Delivery of Metformin and FOXK2 siRNA for Ovarian Cancer Therapy.Small science · 2024Article
- Emerging roles of FOXK2 in cancers and metabolic disorders.Frontiers in oncology · 2024Review
- Circulating circRNA expression profile and its potential role in late recurrence of paroxysmal atrial fibrillation post catheter ablation.Journal of geriatric cardiology : JGC · 2023Article
- FOXK1 regulates Wnt signalling to promote cardiogenesis.Cardiovascular research · 2023Article
- SeATAC: a tool for exploring the chromatin landscape and the role of pioneer factors.Genome biology · 2023Article
- Signal Pathways and microRNAs in Osteosarcoma Growth and the Dual Role of Mesenchymal Stem Cells in Oncogenesis.International journal of molecular sciences · 2023Review
- FOXK1 regulates malignant progression and radiosensitivity through direct transcriptional activation of CDC25A and CDK4 in esophageal squamous cell carcinoma.Scientific reports · 2023Article
- Causal relationship between insulin resistance and sarcopenia.Diabetology & metabolic syndrome · 2023Review
- The impact of senescence on muscle wasting in chronic kidney disease.Journal of cachexia, sarcopenia and muscle · 2023Article
- Time-resolved phosphoproteome and proteome analysis reveals kinase signaling on master transcription factors during myogenesis.iScience · 2022Article
- Natural antisense RNA Foxk1-AS promotes myogenic differentiation by inhibiting Foxk1 activity.Cell communication and signaling : CCS · 2022Article
- ETV2 functions as a pioneer factor to regulate and reprogram the endothelial lineage.Nature cell biology · 2022Article
- The Function of FoxK Transcription Factors in Diseases.Frontiers in physiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
In response to severe injury, adult skeletal muscle exhibits a remarkable regenerative capacity due to a resident muscle stem/progenitor cell population. While a number of factors are expressed in the muscle progenitor cell (MPC) population, the molecular networks that govern this cell population remain an area of active investigation. In this study, utilizing knockdown techniques and overexpression of Foxk1 in the myogenic lineage, we observed dysregulation of Foxo and Mef2 downstream targets. Utilizing an array of technologies, we establish that Foxk1 represses the transcriptional activity of Foxo4 and Mef2 and physically interacts with Foxo4 and Mef2, thus promoting MPC proliferation and antagonizing the myogenic lineage differentiation program, respectively. Correspondingly, knockdown of Foxk1 in C2C12 myoblasts results in cell cycle arrest, and Foxk1 overexpression in C2C12CAR myoblasts retards muscle differentiation. Collectively, we have established that Foxk1 promotes MPC proliferation by repressing Foxo4 transcriptional activity and inhibits myogenic differentiation by repressing Mef2 activity. These studies enhance our understanding of the transcriptional networks that regulate the MPC population and muscle regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.